RE:RE:Create Shareholder ValueA quick answer be "yes"
However, I dont understand the failure to sign more QAPS deals, and if this is one strong leg in the future of the company, i really dont see the progress I expected as a shareholder.
Antigens will remain a core, and my guess is they weill marginally improve the gross margin on these over time.
The main component of my quick answer is Kinlytic.